Drug Profile
Research programme: systemic lupus erythematosus gene therapy - Genovax
Alternative Names: GX 101; Ig-pConsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Genovax
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in Italy (IV, Injection)